The TNF/ADAM 17 system: Implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease

Pharmacogenetics and Genomics

Volumn 16, Issue 10, 2006, Pages 727-734

  Dideberg, Vinciane ^a   Théâtre, Emilie ^a,f   Farnir, Frédéric ^a   Vermeire, Séverine ^c   Rutgeerts, Paul ^c   Vos, Martine De ^d   Belaiche, Jacques ^b   Franchimont, Denis ^e   Gossum, André Van ^e   Louis, Edouard ^b,f   Bours, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e ERASME HOSPITAL   (Belgium)

^f FNRS   (Belgium)

Author keywords

ADAM 17; Crohn's disease; Haplotype; Infliximab; Tumour necrosis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; CAUCASIAN; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; EVALUATION; FEMALE; GENE FUNCTION; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADAM PROTEINS; ADULT; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CROHN DISEASE; DNA PRIMERS; GASTROINTESTINAL AGENTS; HAPLOTYPES; HUMANS; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749010045     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000230117.26581.a4     Document Type: Article

References (31)

1. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32:913-917.
2. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339:89-91.
3. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106:1455-1466.
4. D'Haens G. Anti-TNF therapy for Crohn's disease. Curr Pharm Des 2003; 9:289-294.
5. Van Dullemen HM, Van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135.
6. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029-1034.
7. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
8. Su C, Lichtenstein GR. Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev 2005; 57:237-245.
9. Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics 2004; 5:479-486.
10. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128:376-392.
11. Mascheretti S, Hampe J, Kuhbacher T, Herfarth H, Krawczak M, Folsch UR, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2:127-136.
12. Posch PE, Cruz I, Bradshaw D, Medhekar BA. Novel polymorphisms and the definition of promoter 'alleles' of the tumor necrosis factor and lymphotoxin alpha loci: inclusion in HLA haplotypes. Genes Immun 2003; 4:547-558.
13. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001;120:1347-1355.
14. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with - 308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37:818-824.
15. Black RA. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002; 34:1-5.
16. Itai T, Tanaka M, Nagata S. Processing of tumor necrosis factor by the membrane-bound TNF-alpha-converting enzyme, but not its truncated soluble form. Eur J Biochem 2001; 268:2074-2082.
17. Moss ML, Jin SL, Becherer JD, Bickett DM, Burkhart W, Chen WJ, et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 1997; 72:127-129.
18. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al., ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
19. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
20. Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19:511-519.
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 15:21263-21265.
22. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76:449-462.
23. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
24. Mascheretti S, Hampe J, Croucher PJ, Nikolaus S, Andus T, Schubert S, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12:509-515.
25. Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20:303-310.
26. Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, et al., Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123:106-111.
27. Dideberg V, Louis E, Farnir F, Bertoli S, Vermeire S, Rutgeerts P, et al. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genom 2006; 16:369-373.
28. Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005; 22:613-626.
29. Urcelay E, Mendoza JL, Martinez A, Fernandez L, Taxonera C, Diaz-Rubio M, et al. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J Gastroenterol 2005; 11:1187-1192.
30. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-1094.
31. Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 2004; 126:934-935.